Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

U.S. stock futures fell on Friday following a 25 basis point rate hike by the Bank of Japan. Futures of all four indices declined.

In Malaysia, cases of overweight and obesity are now increasing at an alarming rate. Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's ...

MIAMI, FL / ACCESS Newswire / January 24, 2025 / SMX PLC is solidifying its position as a pivotal partner in developing digital solutions that drive and manage a global circular economy. At the ...

Shares in the NYSE-listed company rose 77% at market open on 24 January 2025, compared to a market close, which occurred shortly after Allurion made the announcement. It is the highest price the ...

Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would ...

--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the ... The gross proceeds to the Company from this offering are expected to be approximately $7.4 million, before deducting the placement ...